Liver adenomas, also called hepatocellular adenomas, are benign tumors that grow in otherwise healthy liver tissue and are overwhelmingly linked to hormonal exposure, particularly oral contraceptive use in women. Long-term users of oral contraceptives have an estimated annual incidence of roughly 3 to 4 per 100,000, and the risk climbs with higher-potency formulations and longer duration of use.1JAMA. Epidemiology of Hepatocellular Adenoma: The Role of Oral Contraceptive Use Most adenomas are harmless and never cause symptoms, but a meaningful fraction can bleed, grow, or in rare cases turn cancerous, which makes understanding when to intervene and when to simply watch a genuinely important question.
How Oral Contraceptives Drive Adenoma Growth
The link between oral contraceptives and liver adenomas has been recognized since the mid-1970s. One of the landmark studies found that women who developed adenomas had used oral contraceptives for an average of about 73 months, compared with roughly 36 months in matched controls. Women with adenomas were also far more likely to have taken formulations containing mestranol, a synthetic estrogen with higher potency than those used in most modern pills.2PubMed. Liver-cell adenomas associated with use of oral contraceptives Older-generation pills delivered substantially more estrogen than today’s low-dose versions, which is one reason the incidence of adenomas has dropped over the decades, though it has not disappeared.
The good news is that stopping oral contraceptives often leads to shrinkage or even complete regression of these tumors. In one early series of three patients, complete regression was documented by imaging after discontinuation of hormonal contraception.3Gastroenterology. Regression of liver cell adenoma: A follow-up study of three consecutive patients after discontinuation of oral contraceptive use A larger retrospective study found that after a median follow-up of about 1.3 years following pill cessation, over a third of adenomas shrank by at least 30%, and about 5% disappeared entirely. The majority of the remaining tumors stayed stable, and only about 1% progressed.4PubMed Central. The effect of oral contraceptive pill cessation on hepatocellular adenoma diameter: A retrospective cohort study Larger adenomas were more likely to regress, probably because their growth was more hormone-dependent in the first place.
Anabolic Steroids and Other Causes
Oral contraceptives get most of the attention, but anabolic androgenic steroids are another well-established trigger. Testosterone and its derivatives can cause a range of liver injuries, including a form of cholestasis, a vascular condition called peliosis hepatis, and both benign and malignant liver tumors.5PubMed Central. Anabolic androgenic steroid-induced liver injury: An update In one reported case, a 27-year-old bodybuilder developed multiple liver adenomas from steroid use, had one surgically removed, and then saw the remaining tumors shrink once he stopped. When he relapsed into steroid use years later, the tumors came back and bled.6PubMed Central. Anabolic steroid abuse causing recurrent hepatic adenomas and hemorrhage Androgenic steroids prescribed for medical conditions like aplastic anemia have also been linked to adenomas, though the overall occurrence appears to be uncommon even among long-term users.7PubMed Central. Multiple hepatocellular adenomas associated with long-term administration of androgenic steroids for aplastic anemia: A case report and literature review
Beyond hormones, certain inherited metabolic conditions raise adenoma risk. Glycogen storage disease type I, a rare condition that disrupts the liver’s ability to manage glucose, predisposes people to hepatocellular adenoma formation and, in some cases, progression to liver cancer.8PubMed. Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I9PubMed Central. Downregulation of pathways implicated in liver inflammation and tumorigenesis of glycogen storage disease type Ia mice receiving gene therapy Obesity and metabolic syndrome have also been increasingly recognized as risk factors, particularly for one molecular subtype discussed below.
Molecular Subtypes and Why They Matter
Not all liver adenomas behave the same way. Over the past two decades, researchers have classified them into distinct subtypes based on genetic mutations, and those subtypes carry meaningfully different risks. The most recent molecular classification recognizes six major subgroups, each linked to specific risk factors, imaging features, and clinical behavior.10PubMed Central. Molecular classification of hepatocellular adenomas: impact on clinical practice The ones that matter most for everyday decisions are:
- HNF1-alpha inactivated: The most common subtype in women, strongly associated with oral contraceptive use. These are typically fatty, bland-looking tumors with a low risk of bleeding or turning malignant. On tissue staining, they lose a specific fat-binding protein that helps pathologists identify them.
- Inflammatory: The second most common type, linked to obesity and metabolic syndrome as well as oral contraceptives. These adenomas produce inflammatory markers like C-reactive protein and serum amyloid A, which can sometimes be detected in blood tests. They carry a moderate bleeding risk.
- Beta-catenin activated (exon 3): The most worrisome subtype. These tumors have the highest risk of transforming into liver cancer, reaching up to 40% in some series. They occur more often in men.
- Beta-catenin activated (exon 7/8): A more recently recognized subtype with a lower cancer risk than exon 3, but an elevated bleeding risk.
- Sonic hedgehog: A subtype associated with a high rate of hemorrhage.
Pathologists can identify these subtypes using a relatively small panel of immunohistochemical stains. Loss of liver fatty acid binding protein points to the HNF1-alpha subtype, serum amyloid A staining identifies inflammatory adenomas, and diffuse glutamine synthetase staining flags beta-catenin-activated tumors.11PubMed Central. Current concepts in the immunohistochemical evaluation of liver tumors In practice, a three-marker panel of glutamine synthetase, beta-catenin, and serum amyloid A can subtype most adenomas without specialized genetic testing.12American Journal of Clinical Pathology. A Limited Immunohistochemical Panel Can Subtype Hepatocellular Adenomas for Routine Practice This matters because clinical decisions, particularly whether to operate, increasingly depend on which subtype a patient has rather than size alone.
Malignant Transformation
The risk of an adenoma turning into hepatocellular carcinoma is the issue that drives the most anxiety. Overall, the risk is low, but it is not zero, and certain factors push it higher. Men are at considerably greater risk than women, which is one reason guidelines recommend removing adenomas in men regardless of size. Tumor size also matters, with larger lesions carrying greater risk. And as mentioned, the beta-catenin exon 3 subtype stands out, with reported transformation rates as high as 40%.13PubMed. Hepatocellular adenomas: review of pathological and molecular features For this reason, the identification of beta-catenin activation on biopsy tends to shift management toward surgery even if the tumor is relatively small.
Symptoms and Bleeding Risk
Most liver adenomas are discovered incidentally on imaging done for other reasons. When they do cause symptoms, the most common complaint is abdominal pain, typically in the upper right or central abdomen. One case report described a 30-year-old woman who presented with acute upper abdominal pain caused by a large adenoma.14PubMed Central. Giant hepatocellular adenoma as cause of severe abdominal pain: a case report In a larger surgical series that included various benign liver tumors, about 70% of patients reported abdominal pain before surgery, and pain scores dropped significantly afterward.
The most dangerous complication is hemorrhage, either bleeding within the tumor itself or rupture into the abdominal cavity. In one large French cohort, about 32% of adenomas were hemorrhagic at presentation.15Annals of Surgery. Hepatocellular Adenoma Risk Factors of Hemorrhage: Size Is Not the Only Concern! Size is a risk factor, but it is far from the only one. That same study found that the sonic hedgehog subtype carried a dramatically higher bleeding risk, as did beta-catenin exon 7/8 mutations and chronic alcohol consumption. A separate analysis identified additional risk factors for bleeding: tumors 35 mm or larger, those protruding from the liver surface (exophytic growth), tumors located in the left lateral liver segments, and those with visible arteries on imaging.16BJS. Risk factors for bleeding in hepatocellular adenoma These features help clinicians identify which small-seeming adenomas may still be dangerous.
How Adenomas Are Diagnosed
The workhorse of adenoma diagnosis is contrast-enhanced MRI, particularly using a liver-specific contrast agent called gadoxetic acid. This agent is taken up by normal liver cells during a delayed “hepatobiliary phase” of imaging but is not absorbed well by adenoma cells, creating a characteristic dark appearance on the scan. Focal nodular hyperplasia, a common benign liver lesion that can mimic an adenoma on standard imaging, does absorb the contrast and lights up, making the two relatively easy to distinguish. A systematic review of studies using this technique found sensitivity for diagnosing adenomas consistently above 91% and specificity above 87%.17PubMed. Focal Nodular Hyperplasia and Hepatocellular Adenoma: Accuracy of Gadoxetic Acid-enhanced MR Imaging–A Systematic Review Individual studies have reported sensitivity reaching 96% when the hepatobiliary phase images are specifically reviewed.18PubMed. Diagnostic accuracy of MRI in differentiating hepatocellular adenoma from focal nodular hyperplasia: prospective study of the additional value of gadoxetate disodium
MRI can also provide clues about the subtype. Fat-rich adenomas on MRI often correspond to the HNF1-alpha subtype, while those that show persistent contrast enhancement and certain signal patterns may be inflammatory. However, confidently identifying the beta-catenin subtypes on imaging alone remains difficult, which is why biopsy with immunohistochemistry is sometimes needed, particularly when the management decision hinges on subtype.
Management Decisions
The first step for nearly all women diagnosed with a liver adenoma while on hormonal contraception is straightforward: stop the pill and switch to a non-hormonal method. Similarly, anyone using anabolic steroids is advised to discontinue. Weight loss is recommended for patients who are obese, since metabolic factors contribute to adenoma growth in some subtypes. After these lifestyle changes, repeat imaging at six-month intervals tracks whether the tumor shrinks, stays stable, or grows.
Surgery enters the picture under several circumstances. Most guidelines agree on a few key thresholds: women with adenomas that remain 5 cm or larger after a period of observation and lifestyle modification should be considered for resection, because of the higher bleeding and malignancy risk associated with large tumors.19PubMed. Management of Hepatocellular Adenoma: Recent Advances All adenomas in men are generally recommended for removal regardless of size, because of the elevated risk of cancer in male patients.20PubMed. Guidelines for the Treatment of Hepatocellular Adenoma in the Era of Molecular Biology: An Experience-Based Surgeons’ Perspective Both ACG and EASL guidelines also suggest that surgical resection be considered if a lesion increases by 20% or more during surveillance, even if it has not hit the 5 cm threshold.21PubMed Central. Nonoperative Management of Hepatic Adenomas: A Review
The growing role of molecular subtyping is shifting these thresholds. Some surgical centers now recommend resection for all non-steatotic (non-fatty) adenomas over 5 cm in women and for any adenoma in men, with the subtype informing how urgently to operate.20PubMed. Guidelines for the Treatment of Hepatocellular Adenoma in the Era of Molecular Biology: An Experience-Based Surgeons’ Perspective A confirmed beta-catenin exon 3 mutation is increasingly treated as a reason for resection even if the tumor is small, because of the high cancer risk.
Non-Surgical Alternatives
Not every adenoma needs to come out with a scalpel. Two interventional radiology techniques have emerged for patients who are poor surgical candidates or who want to avoid a major operation.
Transarterial embolization involves threading a catheter through the groin artery into the blood vessel feeding the tumor and injecting tiny particles to cut off its blood supply. In a series of 59 patients who underwent this procedure, the complication rate was about 12%, with most complications manageable. No patient experienced clinically obvious bleeding or rebleeding of a treated adenoma during follow-up. However, one patient who had emergency embolization for a ruptured, actively bleeding adenoma died three months later from aspiration pneumonia, underscoring that emergency scenarios carry higher risk than elective ones.22BJS. Safety and efficacy of transarterial embolization of hepatocellular adenomas A smaller series reported a median reduction in tumor volume of about 67%, though responses varied widely from near-complete shrinkage to some growth.23PubMed Central. Bland Embolization of Benign Liver Tumors: Review of the Literature and a Single Center Experience
Radiofrequency ablation, where a needle-like probe is inserted through the skin and delivers heat to destroy the tumor, has also been used for small adenomas. Early experience suggests it is safe and effective for carefully selected patients with tumors small enough to be treated in a single session.24PubMed. Successful treatment of hepatocellular adenoma with percutaneous radiofrequency ablation Neither embolization nor ablation is considered standard first-line treatment, but both offer options when surgery carries excessive risk or the patient prefers a less invasive approach.
Pregnancy and Liver Adenomas
This is one of the trickiest areas in adenoma management, because the patients are typically young women of childbearing age, and pregnancy itself floods the body with hormones that can fuel tumor growth. The fear has long been that a growing adenoma could rupture during pregnancy, endangering both mother and baby. One study reported four cases of adenoma growth during pregnancy, one of which required a cesarean section at 34 to 36 weeks because of assumed rupture risk. In one case, radiofrequency ablation was performed during the first trimester to prevent problems later. But in the remaining 14 cases followed in the same study, pregnancies progressed without incident and outcomes for mother and child were fine.25PubMed. Management of hepatocellular adenoma during pregnancy
The current thinking at experienced liver centers is more permissive than the old blanket advice to avoid pregnancy. Women with adenomas smaller than 5 cm are increasingly told that pregnancy is not automatically off the table, provided they receive close monitoring with ultrasound throughout. The reasoning is that the biological behavior of these tumors may be less threatening than was historically assumed, and a blanket prohibition on pregnancy carries its own psychological and life-planning costs for young women.26PubMed Central. The management of pregnancy in women with hepatocellular adenoma: a plea for an individualized approach For women with large or previously complicated adenomas, the calculus is different, and pre-pregnancy resection is often recommended. These decisions require a conversation that weighs the specific tumor’s size, subtype, and behavior against the patient’s reproductive goals.
When Adenomas Show Up in Men
Liver adenomas in men are uncommon, but they tend to behave more aggressively. Men are more likely to harbor the beta-catenin-activated subtypes and face a higher rate of transformation to liver cancer.13PubMed. Hepatocellular adenomas: review of pathological and molecular features This is why most guidelines take a simpler approach for male patients: resect, regardless of size.19PubMed. Management of Hepatocellular Adenoma: Recent Advances The threshold for watchful waiting that applies to many women with small, stable tumors does not apply here. Men who are diagnosed with an adenoma, whether found incidentally or after symptoms, can generally expect a recommendation for surgical removal as the default plan. Anabolic steroid use is the most common identifiable cause in men, and discontinuation is still advised even when surgery is planned, both to reduce the risk of recurrence and to address any other steroid-related liver damage.